Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simtuzumab in Myelofibrosis
NCT01369498Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Jun 2011
- Primary completion
- Jun 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of simtuzumab in myelofibrosis (MF) (4 arms), sponsored by Gilead Sciences. Primary endpoint: Rate of Clinical Response as Defined by the Percentage of Participants With Reduction in Bone Marrow Fibrosis Score at 24 weeks. Started Jun 2011; status: completed.
02
Drugs
simtuzumab
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT01369498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01369498.